BPCR vs. PHLL, ATST, BUR, BPT, JGGI, EMG, 3IN, ABDN, RCP, and MNKS
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include Petershill Partners (PHLL), Alliance Trust (ATST), Burford Capital (BUR), Bridgepoint Group (BPT), JPMorgan Global Growth & Income (JGGI), Man Group (EMG), 3i Infrastructure (3IN), abrdn (ABDN), RIT Capital Partners (RCP), and Monks (MNKS). These companies are all part of the "asset management" industry.
BioPharma Credit vs.
BioPharma Credit (LON:BPCR) and Petershill Partners (LON:PHLL) are both financial services companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations, community ranking and institutional ownership.
41.5% of BioPharma Credit shares are held by institutional investors. Comparatively, 89.3% of Petershill Partners shares are held by institutional investors. 6.2% of BioPharma Credit shares are held by company insiders. Comparatively, 0.7% of Petershill Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Petershill Partners has a consensus price target of GBX 245.33, suggesting a potential downside of 6.72%. Given Petershill Partners' stronger consensus rating and higher possible upside, analysts clearly believe Petershill Partners is more favorable than BioPharma Credit.
BioPharma Credit has higher revenue and earnings than Petershill Partners. BioPharma Credit is trading at a lower price-to-earnings ratio than Petershill Partners, indicating that it is currently the more affordable of the two stocks.
BioPharma Credit received 69 more outperform votes than Petershill Partners when rated by MarketBeat users. However, 100.00% of users gave Petershill Partners an outperform vote while only 64.62% of users gave BioPharma Credit an outperform vote.
In the previous week, Petershill Partners had 1 more articles in the media than BioPharma Credit. MarketBeat recorded 1 mentions for Petershill Partners and 0 mentions for BioPharma Credit. Petershill Partners' average media sentiment score of 0.67 beat BioPharma Credit's score of 0.00 indicating that Petershill Partners is being referred to more favorably in the news media.
BioPharma Credit has a net margin of 80.20% compared to Petershill Partners' net margin of 59.57%. BioPharma Credit's return on equity of 8.51% beat Petershill Partners' return on equity.
BioPharma Credit has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Petershill Partners has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.
BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 819.7%. Petershill Partners pays an annual dividend of GBX 12 per share and has a dividend yield of 4.6%. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Petershill Partners pays out 48.7% of its earnings in the form of a dividend.
Summary
Petershill Partners beats BioPharma Credit on 13 of the 20 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 2/22/2025 by MarketBeat.com Staff
